---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-019229"
form_type: "8-K"
ticker: null
cik: "0001504167"
company_name: "TREX WIND-DOWN, INC."
filed_at: "2023-07-03T23:59:59+00:00"
generated_at: "2026-06-13T13:13:50.928180+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Timber Pharma receives NYSE American delisting notice for stockholders' deficit of $1.3M

## Summary
- Stockholders' deficit of $1.3M as of March 31, 2023 triggers non-compliance with Sections 1003(a)(i) and (ii).
- Company must submit compliance plan by July 28, 2023; deadline to regain compliance is December 28, 2024.
- Common stock (TMBR) continues trading but with added '.BC' designation for below compliance.
- Failure to submit or execute plan may lead to delisting, reducing liquidity and financing options.

## SEC filing metadata
- accession: 0001437749-23-019229
- form_type: 8-K
- cik: 0001504167
- company_name: TREX WIND-DOWN, INC.
- filed_at: 2023-07-03T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1504167/000143774923019229/0001437749-23-019229-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1504167/000143774923019229/tmbr20230630_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-019229
- JSON: https://secwatch.observer/filing/0001437749-23-019229.json
- Plain text: https://secwatch.observer/filing/0001437749-23-019229.txt

## Key facts
- Listing & Compliance Notices
  TREX WIND-DOWN, INC. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii)).
  - Exchange: nyse american
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 1003(a)(i), 1003(a)(ii)
  source text: June 28, 2023, Timber Pharmaceuticals, Inc. (the “ Company ”) received a deficiency letter (the “ Deficiency Letter ”) from the NYSE American LLC (the “ NYSE American ”) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(i) and (ii) of the NYSE American Company Guide. Section 1003(a)(i) of the NYSE American Company Guide requires a listed company’s stockholders’ equity be at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years. Section
  evidence_url: https://www.sec.gov/Archives/edgar/data/1504167/000143774923019229/0001437749-23-019229-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.